{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:52:32Z","timestamp":1782276752876,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009401","name":"Medizinischen Fakult\u00e4t, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","award":["Medical"],"award-info":[{"award-number":["Medical"]}],"id":[{"id":"10.13039\/501100009401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009401","name":"Medizinischen Fakult\u00e4t, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","award":["Clinician Scientist Program (MCSP)"],"award-info":[{"award-number":["Clinician Scientist Program (MCSP)"]}],"id":[{"id":"10.13039\/501100009401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00467-024-06512-4","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T20:42:02Z","timestamp":1727296922000},"page":"423-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM disease"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-4248","authenticated-orcid":false,"given":"Richard","family":"Klaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Kanzelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-7813","authenticated-orcid":false,"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-3459","authenticated-orcid":false,"given":"B\u00e4rbel","family":"Lange-Sperandio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"6512_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2215\/cjn.04290417","volume":"13","author":"EE van Daalen","year":"2018","unstructured":"van Daalen EE, Jennette JC, McAdoo SP, Pusey CD, Alba MA, Poulton CJ, Wolterbeek R, Nguyen TQ, Goldschmeding R, Alchi B, Griffiths M, de Zoysa JR, Vincent B, Bruijn JA, Bajema IM (2018) Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol 13:63\u201372. https:\/\/doi.org\/10.2215\/cjn.04290417","journal-title":"Clin J Am Soc Nephrol"},{"key":"6512_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/pr.2017.315","volume":"83","author":"CP Menzi","year":"2018","unstructured":"Menzi CP, Bucher BS, Bianchetti MG, Ardissino G, Simonetti GD (2018) Management and outcomes of childhood Goodpasture\u2019s disease. Pediatr Res 83:813\u2013817. https:\/\/doi.org\/10.1038\/pr.2017.315","journal-title":"Pediatr Res"},{"key":"6512_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney disease: improving global outcomes glomerular diseases work group","year":"2021","unstructured":"Kidney disease: improving global outcomes glomerular diseases work group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"6512_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00467-021-05333-z","volume":"37","author":"T Dowsett","year":"2022","unstructured":"Dowsett T, Oni L (2022) Anti-glomerular basement membrane disease in children: a brief overview. Pediatr Nephrol 37:1713\u20131719. https:\/\/doi.org\/10.1007\/s00467-021-05333-z","journal-title":"Pediatr Nephrol"},{"key":"6512_CR5","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s10067-012-2062-9","volume":"31","author":"A Bayat","year":"2012","unstructured":"Bayat A, Kamperis K, Herlin T (2012) Characteristics and outcome of Goodpasture\u2019s disease in children. Clin Rheumatol 31:1745\u20131751. https:\/\/doi.org\/10.1007\/s10067-012-2062-9","journal-title":"Clin Rheumatol"},{"key":"6512_CR6","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3389\/fimmu.2019.01665","volume":"10","author":"C Marques","year":"2019","unstructured":"Marques C, Carvelli J, Biard L, Faguer S, Prov\u00f4t F, Matignon M, Boffa JJ, Plaisier E, Hertig A, Touzot M, Moranne O, Belenfant X, Annane D, Qu\u00e9m\u00e9neur T, Cadranel J, Izzedine H, Br\u00e9chot N, Cacoub P, Piedrafita A, Jourde-Chiche N, Saadoun D (2019) Prognostic factors in anti-glomerular basement membrane disease: a multicenter study of 119 patients. Front Immunol 10:1665. https:\/\/doi.org\/10.3389\/fimmu.2019.01665","journal-title":"Front Immunol"},{"key":"6512_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nefroe.2021.05.005","volume":"41","author":"K Abe","year":"2021","unstructured":"Abe K, Shimamura Y, Nishizawa K, Maeda T, Yane K, Shinohara T, Ogawa Y, Takizawa H (2021) A case of relapsed anti-glomerular basement membrane glomerulonephritis complicated by IgG4-related disease. Nefrolog\u00eda (English Edition) 41:352\u2013354. https:\/\/doi.org\/10.1016\/j.nefroe.2021.05.005","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"6512_CR8","doi-asserted-by":"publisher","first-page":"c59","DOI":"10.1159\/000072022","volume":"94","author":"M Segelmark","year":"2003","unstructured":"Segelmark M, Hellmark T, Wieslander J (2003) The prognostic significance in Goodpasture\u2019s disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 94:c59-68. https:\/\/doi.org\/10.1159\/000072022","journal-title":"Nephron Clin Pract"},{"key":"6512_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","volume":"134","author":"JB Levy","year":"2001","unstructured":"Levy JB, Turner AN, Rees AJ, Pusey CD (2001) Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134:1033\u20131042. https:\/\/doi.org\/10.7326\/0003-4819-134-11-200106050-00009","journal-title":"Ann Intern Med"},{"key":"6512_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00467-014-2897-1","volume":"30","author":"R Gajjar","year":"2015","unstructured":"Gajjar R, Miller SD, Meyers KE, Ginsberg JP (2015) Fertility preservation in patients receiving cyclophosphamide therapy for renal disease. Pediatr Nephrol 30:1099\u20131106. https:\/\/doi.org\/10.1007\/s00467-014-2897-1","journal-title":"Pediatr Nephrol"},{"key":"6512_CR11","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1002\/1097-0142(19921201)70:11<2703::aid-cncr2820701123>3.0.co;2-x","volume":"70","author":"ML Meistrich","year":"1992","unstructured":"Meistrich ML, Wilson G, Brown BW, da Cunha MF, Lipshultz LI (1992) Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer 70:2703\u20132712. https:\/\/doi.org\/10.1002\/1097-0142(19921201)70:11%3c2703::aid-cncr2820701123%3e3.0.co;2-x","journal-title":"Cancer"},{"key":"6512_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2215\/cjn.08570722","volume":"18","author":"EY Chan","year":"2023","unstructured":"Chan EY, Yap DY, Colucci M, Ma AL, Parekh RS, Tullus K (2023) Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 18:533\u2013548. https:\/\/doi.org\/10.2215\/cjn.08570722","journal-title":"Clin J Am Soc Nephrol"},{"key":"6512_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jpeds.2017.05.002","volume":"187","author":"I Mahmoud","year":"2017","unstructured":"Mahmoud I, Jellouli M, Boukhris I, Charfi R, Ben Tekaya A, Saidane O, Ferjani M, Hammi Y, Trabelsi S, Khalfallah N, Tekaya R, Gargah T, Abdelmoula L (2017) Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review. J Pediatr 187:213-219.e212. https:\/\/doi.org\/10.1016\/j.jpeds.2017.05.002","journal-title":"J Pediatr"},{"key":"6512_CR14","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1093\/ndt\/gfad090","volume":"38","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura M, Gauckler P, Anders HJ, Bruchfeld A, Fernandez-Juarez GM, Floege J, Frangou E, Goumenos D, Segelmark M, Turkmen K, van Kooten C, Tesar V, Geetha D, Fervenza FC, Jayne DRW, Stevens KI, Kronbichler A (2023) Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines\/recommendations. Nephrol Dial Transplant 38:2637\u20132651. https:\/\/doi.org\/10.1093\/ndt\/gfad090","journal-title":"Nephrol Dial Transplant"},{"key":"6512_CR15","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2215\/cjn.01070118","volume":"13","author":"LM Gomez Mendez","year":"2018","unstructured":"Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall\u2019Era M, Looney RJ, Rovin B, Dragone L, Brunetta P (2018) Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13:1502\u20131509. https:\/\/doi.org\/10.2215\/cjn.01070118","journal-title":"Clin J Am Soc Nephrol"},{"key":"6512_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/acr2.11074","volume":"1","author":"C Mitchell","year":"2019","unstructured":"Mitchell C, Crayne CB, Cron RQ (2019) Patterns of B cell repletion following rituximab therapy in a pediatric rheumatology cohort. ACR Open Rheumatol 1:527\u2013532. https:\/\/doi.org\/10.1002\/acr2.11074","journal-title":"ACR Open Rheumatol"},{"key":"6512_CR17","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.55563\/clinexprheumatol\/yqjz1s","volume":"41","author":"A Nassar-Sheikh Rashid","year":"2023","unstructured":"Nassar-Sheikh Rashid A, Bergkamp SC, Kampinga RE, Gouw SC, Bouts AHM, Oosterveld MJS, Baars PA, van Leeuwen EMM, Kuijpers TW, van den Berg JM, Schonenberg-Meinema D (2023) Pharmacodynamics of rituximab in paediatric immune mediated diseases: B cell depletion and repopulation, effects on immunoglobulin levels and risk for infections. Clin Exp Rheumatol 41:2323\u20132330. https:\/\/doi.org\/10.55563\/clinexprheumatol\/yqjz1s","journal-title":"Clin Exp Rheumatol"},{"key":"6512_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12882-018-1038-7","volume":"19","author":"M Heitz","year":"2018","unstructured":"Heitz M, Carron PL, Clavarino G, Jouve T, Pinel N, Guebre-Egziabher F, Rostaing L (2018) Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease. BMC Nephrol 19:241. https:\/\/doi.org\/10.1186\/s12882-018-1038-7","journal-title":"BMC Nephrol"},{"key":"6512_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ekir.2018.12.002","volume":"4","author":"R Jain","year":"2019","unstructured":"Jain R, Dgheim H, Bomback AS (2019) Rituximab for anti-glomerular basement membrane disease. Kidney Int Rep 4:614\u2013618. https:\/\/doi.org\/10.1016\/j.ekir.2018.12.002","journal-title":"Kidney Int Rep"},{"key":"6512_CR20","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2169\/internalmedicine.0166-22","volume":"62","author":"K Kanaoka","year":"2023","unstructured":"Kanaoka K, Ihara S, Nakatani T, Minami S (2023) Rituximab for the treatment of anti-glomerular basement membrane disease with isolated diffuse alveolar hemorrhage. Intern Med 62:1971\u20131975. https:\/\/doi.org\/10.2169\/internalmedicine.0166-22","journal-title":"Intern Med"},{"key":"6512_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2015.04.003","volume":"60","author":"M Touzot","year":"2015","unstructured":"Touzot M, Poisson J, Faguer S, Ribes D, Cohen P, Geffray L, Anguel N, Francois H, Karras A, Cacoub P, Durrbach A, Saadoun D (2015) Rituximab in anti-GBM disease: a retrospective study of 8 patients. J Autoimmun 60:74\u201379. https:\/\/doi.org\/10.1016\/j.jaut.2015.04.003","journal-title":"J Autoimmun"},{"key":"6512_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/0886022x.2022.2097405","volume":"44","author":"XF Yang","year":"2022","unstructured":"Yang XF, Jia XY, Yu XJ, Cui Z, Zhao MH (2022) Rituximab for the treatment of refractory anti-glomerular basement membrane disease. Ren Fail 44:1123\u20131129. https:\/\/doi.org\/10.1080\/0886022x.2022.2097405","journal-title":"Ren Fail"},{"key":"6512_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/ndt\/gfad268","volume":"39","author":"L Chen","year":"2024","unstructured":"Chen L, Chen Y, Ni A, Lin Y, Shen X, Chen J, Han F (2024) Efficacy of rituximab for patients with anti-glomerular basement membrane disease. Nephrol Dial Transplant 39:720\u2013723. https:\/\/doi.org\/10.1093\/ndt\/gfad268","journal-title":"Nephrol Dial Transplant"},{"key":"6512_CR24","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s00345-018-2588-9","volume":"37","author":"S Abdovic","year":"2019","unstructured":"Abdovic S, Cuk M, Cekada N, Milosevic M, Geljic A, Fusic S, Bastic M, Bahtijarevic Z (2019) Predicting posterior urethral obstruction in boys with lower urinary tract symptoms using deep artificial neural network. World J Urol 37:1973\u20131979. https:\/\/doi.org\/10.1007\/s00345-018-2588-9","journal-title":"World J Urol"},{"key":"6512_CR25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1084\/jem.126.6.989","volume":"126","author":"RA Lerner","year":"1967","unstructured":"Lerner RA, Glassock RJ, Dixon FJ (1967) The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 126:989\u20131004. https:\/\/doi.org\/10.1084\/jem.126.6.989","journal-title":"J Exp Med"},{"key":"6512_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clim.2005.02.016","volume":"116","author":"Z Cui","year":"2005","unstructured":"Cui Z, Zhao MH (2005) Avidity of anti-glomerular basement membrane autoantibodies was associated with disease severity. Clin Immunol 116:77\u201382. https:\/\/doi.org\/10.1016\/j.clim.2005.02.016","journal-title":"Clin Immunol"},{"key":"6512_CR27","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1046\/j.1523-1755.1999.055003936.x","volume":"55","author":"T Hellmark","year":"1999","unstructured":"Hellmark T, Segelmark M, Unger C, Burkhardt H, Saus J, Wieslander J (1999) Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int 55:936\u2013944. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.055003936.x","journal-title":"Kidney Int"},{"key":"6512_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.humimm.2009.04.004","volume":"70","author":"J Zhao","year":"2009","unstructured":"Zhao J, Yan Y, Cui Z, Yang R, Zhao MH (2009) The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity. Hum Immunol 70:425\u2013429. https:\/\/doi.org\/10.1016\/j.humimm.2009.04.004","journal-title":"Hum Immunol"},{"key":"6512_CR29","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.2215\/cjn.01380217","volume":"12","author":"SP McAdoo","year":"2017","unstructured":"McAdoo SP, Pusey CD (2017) Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol 12:1162\u20131172. https:\/\/doi.org\/10.2215\/cjn.01380217","journal-title":"Clin J Am Soc Nephrol"},{"key":"6512_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:417\u2013427. https:\/\/doi.org\/10.1056\/NEJMoa1213277","journal-title":"New Engl J Med"},{"key":"6512_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000017801","volume":"98","author":"M Uematsu-Uchida","year":"2019","unstructured":"Uematsu-Uchida M, Ohira T, Tomita S, Satonaka H, Tojo A, Ishimitsu T (2019) Rituximab in treatment of anti-GBM antibody glomerulonephritis: a case report and literature review. Medicine (Baltimore) 98:e17801. https:\/\/doi.org\/10.1097\/md.0000000000017801","journal-title":"Medicine (Baltimore)"},{"key":"6512_CR32","doi-asserted-by":"publisher","unstructured":"Narayanan M, Casimiro I, Pichler R (2014) A unique way to treat Goodpasture\u2019s disease. BMJ Case Rep 2014:bcr2014206220 https:\/\/doi.org\/10.1136\/bcr-2014-206220","DOI":"10.1136\/bcr-2014-206220"},{"key":"6512_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/qjmed\/hcr001","volume":"105","author":"Y Shah","year":"2012","unstructured":"Shah Y, Mohiuddin A, Sluman C, Daryanani I, Ledson T, Banerjee A, Crowe A, McClelland P (2012) Rituximab in anti-glomerular basement membrane disease. QJM 105:195\u2013197. https:\/\/doi.org\/10.1093\/qjmed\/hcr001","journal-title":"QJM"},{"key":"6512_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ncpneph0724","volume":"4","author":"E Wechsler","year":"2008","unstructured":"Wechsler E, Yang T, Jordan SC, Vo A, Nast CC (2008) Anti-glomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol 4:167\u2013171. https:\/\/doi.org\/10.1038\/ncpneph0724","journal-title":"Nat Clin Pract Nephrol"},{"key":"6512_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-024-01892-0","author":"S Arnaert","year":"2024","unstructured":"Arnaert S, Schepens N, Deleu L, Malfait T (2024) Case report: renal recovery in Goodpasture\u2019s syndrome treated with rituximab. J Nephrol. https:\/\/doi.org\/10.1007\/s40620-024-01892-0","journal-title":"J Nephrol"},{"key":"6512_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5414\/cn107333","volume":"80","author":"M Mori","year":"2013","unstructured":"Mori M, Nwaogwugwu U, Akers GR, McGill RL (2013) Anti-glomerular basement membrane disease treated with mycophenolate mofetil, corticosteroids, and plasmapheresis. Clin Nephrol 80:67\u201371. https:\/\/doi.org\/10.5414\/cn107333","journal-title":"Clin Nephrol"},{"key":"6512_CR37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172:757\u2013764. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.1323","journal-title":"JAMA Pediatr"},{"key":"6512_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/ndt\/gfad132","volume":"39","author":"L Tyrberg","year":"2023","unstructured":"Tyrberg L, Andersson F, Uhlin F, Hellmark T, Segelmark M (2023) Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment. Nephrol Dial Transplant 39:45\u201354. https:\/\/doi.org\/10.1093\/ndt\/gfad132","journal-title":"Nephrol Dial Transplant"},{"key":"6512_CR39","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1681\/asn.2021111460","volume":"33","author":"F Uhlin","year":"2022","unstructured":"Uhlin F, Szpirt W, Kronbichler A, Bruchfeld A, Soveri I, Rostaing L, Daugas E, Lionet A, Kamar N, Rafat C, Myslive\u010dek M, Tesa\u0159 V, Fernstr\u00f6m A, Kjellman C, Elfving C, McAdoo S, M\u00f6lne J, Bajema I, Sonesson E, Segelmark M (2022) Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: an open-label phase 2a study. J Am Soc Nephrol 33:829\u2013838. https:\/\/doi.org\/10.1681\/asn.2021111460","journal-title":"J Am Soc Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06512-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T19:02:26Z","timestamp":1734980546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06512-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6512"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06512-4","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}